Financials and valuation
Following the completion of the stake sale in CME, Creo has restated its FY24 and
FY23 financials to reflect CME as discontinued operations. FY24 group revenues are
therefore restated to be £4.0m, derived entirely from core technology products (including
Speedboat and the CROMA platform). The corresponding figure for FY23 was £2.3m, although
the company also recorded an additional £1.7m in milestone payments from the Kamaptive
agreement with Intuitive that year. The lack of milestone payments, which has a direct
flow-through impact on profitability, was reflected in the FY24 gross margins, declining
to 46.6%, from 58.6% in FY23. Adjusting for the Kamaptive inflows, the gross margin
improved to 44.5% from 40.2% in FY23, according to management. We expect the gross
margins to improve further as revenues scale with the launch and uptake of Creo’s
core devices and growth in the installed base of CROMA systems.
During FY24, the total operating loss increased by 7.1% to £28.8m (FY23: £26.9m).
Management attributes this to the absence of the Kamaptive contribution (£0.8m in
FY23) and lower R&D tax credits received during the year (£2.0m vs £2.8m in FY23),
following R&D tax relief reforms in the UK announced in early 2023. Underlying administrative
charges stayed broadly unchanged at £23.8m (£23.6m in FY23). We understand that this
includes £11.1m in R&D costs in FY24 versus £11.8m in the prior year. In H224, Creo
implemented stringent cost rationalisation measures, which management expects will
generate £5m in cost savings in FY25, with further savings anticipated beyond 2025.
Estimates revision
We have adjusted our model to account for the additional disclosures related to the
51% stake sale in CME. For our long-term topline and profitability forecasts, we keep
our underlying assumptions unchanged from our last update note.
We continue to assume that the core technology revenues will be driven by the Speedboat
franchise and SpydrBlade Flex, which reported its first commercial sales in Q125.
For MicroBlate Flex, we currently assume revenue will be generated solely through
the partnership with Intuitive, which we reflect separately as Kamaptive partnering
revenues. Our model does not yet include contribution from MicroBlate Fine, which
management plans to release on a limited basis in Q225. MicroBlate Fine is, to our
knowledge, the smallest available microwave ablation device, with a diameter of less
than 1mm, enabling it to access hard-to-reach organs such as the pancreas. We believe
that pancreatic lesions will be the initial focus for the company. We will review
our model to include MicroBlate Fine as more details become available, noting the
potential upside from inclusion.
For FY25, we estimate core revenues of £6.1m, of which £0.5m will be contributed by
SpydrBlade and the remainder by Speedboat. We assume gross margins of 50% for Speedboat
and 60% for SpydrBlade in FY25, rising to a peak of 70% and 75%, respectively. We
estimate per-device pricing of £1,500–1,600 for SpydrBlade Flex and £750–800 for Speedboat,
assuming a 2% annual increase. As with MicroBlate Flex, our model currently does not
incorporate any revenue from the sale of the CROMA box (priced at c £20,000) on the
assumption that with rising device orders, the system would be bundled free of cost.
If not, this could add another potential revenue stream for Creo.
Under the Kamaptive partnerships, we continue to consider only the potential inflows
from the deal with Intuitive. As noted in our previous update, we only model one additional
milestone payment from the deal, worth £0.5m in 2026, on commencement of clinical
trials in the US and China. We expect full commercial sales for MicroBlate Flex to
begin from 2026 and estimate net proceeds of £500 per device from the partnership.
We model an initial penetration level of 0.2% in 2026 and peak penetration of 10%
in 2031 (as a percentage of total procedures performed by the Ion robots). We assume
that 100 procedures per year will be performed per installed Ion system and estimate
a total of 1,475 Ion robots to be installed in 2026, rising to 3,500 by 2030. This
translates to revenues of £0.6m from partnerships in 2026, increasing year-on-year
to reach £5.6m in 2030.
We present our assumptions and forecasts in Exhibit 3.
Exhibit 3: Creo Medical revenue and margin forecasts |
 |
Source: Edison Investment Research |